News

126 to 135 of 95927 results

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

14-08-2014

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals,…

Advanced refractory multiple myelomaAmgenBiotechnologyKyprolisOncologyOnyx PharmaceuticalsResearchUSA

RedHill and RESprotect sign exclusive deal over cancer drug

RedHill and RESprotect sign exclusive deal over cancer drug

14-08-2014

Israeli biotech firm RedHill Biopharma and privately-held German biotech company RESprotect GmbH have…

Dror Ben-AsherGermanyIsraelLicensingOncologyPancreatic cancerPharmaceuticalRedHill BiopharmaRESprotectSouth Korea

Sanofi Pasteur announces positive results for Fluzone’s higher dose

Sanofi Pasteur announces positive results for Fluzone’s higher dose

14-08-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, has found that Fluzone High-Dose was…

Anti-viralsFluzonePharmaceuticalResearchSanofiSanofi PasteurUSAVaccinationVaccines

New treatments will partially compensate for unipolar depression drugs coming out of patent

New treatments will partially compensate for unipolar depression drugs coming out of patent

14-08-2014

New antidepressants and antipsychotics will offset a steep decline in sales following genericization…

Antidepressant therapiesDecision Resources GroupGlobalMarkets & MarketingNeurologicalPharmaceuticalPsychiatryUnipolar depression

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Vertex to drop hep C drug Incivek following poor sales

14-08-2014

Struggling US Biotech firm Vertex Pharmaceuticals has said it will cease marketing its hepatitis C treatment…

Anti-viralsBiotechnologyGilead SciencesHepatitis C treatmentIncivekJohnson & JohnsonMarkets & MarketingSovaldiTelaprevirUSAVertex Pharmaceuticals

Celltrion files for US FDA approval of Remsima biosimilar

Celltrion files for US FDA approval of Remsima biosimilar

13-08-2014

South Korean biopharmaceutical firm Celltrion says it has completed the filing procedure to obtain US…

BiosimilarsBiotechnologyCellTrionClinical researchInflammatory diseasesinfliximabJanssen BiotechJohnson & JohnsonPatentsRegulationRemicadeRemsimaUSA

Rigel’s R348 fails to meet endpoints in Ph II dry eye study

13-08-2014

Clinical-stage US drug developer Rigel Pharmaceuticals says that R348, its ophthalmic JAK/SYK inhibitor,…

BiotechnologyDry eye diseasefostamatinibOphthalmicsR118R348ResearchRigel Pharmaceuticals

New Zealand to fund Vidaza and Revlimid

New Zealand to fund Vidaza and Revlimid

13-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC says it has approved a proposal for funding…

Celgene Corp.FinancialHealthcareNew ZealandPharmaceuticalPricingRevlimidVidaza

126 to 135 of 95927 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top